Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Inhibition of quorum sensing-mediated processes in bacteria

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

Inhibition of quorum sensing-mediated processes in bacteria

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES

The present invention provides high-complexity defined gut microbial communities capable of achieving substantial engraftment and having stability following human fecal community microbial challenge and methods of producing the same. Also provided are methods of using high-complexity defined gut microbial communities for the treatment of dysbiosis or a pathological condition in an animal.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

INHIBITION OF QUORUM SENSING-MEDIATED PROCESSES IN BACTERIA

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

Inhibition of quorum sensing-mediated processes in bacteria

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

INFLUENZA A H7N9 VIRUS THERAPIES

The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same. 1. A method for preventing or treating influenza A H7N9 virus infection , the method comprising administering to a subject having or at risk for having influenza A H7N9 virus infection a therapeutically effective amount of an antibody , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:56;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:57;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:58;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:59;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:60; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:61.2. The method of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:74.3. The method of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:75.4. The method of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:74 claim 1 , and the light chain variable region comprises the amino acid sequence of SEQ ID NO:75.5. The method of claim 1 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:76.6. The method of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:77.7. The method of claim 1 , wherein the antibody comprises a heavy chain and a light chain claim 1 , wherein the heavy chain comprises the amino acid ...

INHIBITION OF QUORUM SENSING-MEDIATED PROCESSES IN BACTERIA

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same. 1. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza B virus hemagglutinin , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:63;(b) HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:67, 68, 69, 70, 71, 72, 73, and 74;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:77;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:56;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:58; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:60.2. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:91.3. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.4. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region and a heavy chain variable region claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:91 claim 1 , and the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.5. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain comprising the amino ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 153.-. (canceled)54. An isolated nucleic acid encoding an anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;(c) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:180 and 181;(d) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:182, 183, 184, 185, and 186;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and(f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:188, 189, and 190.55. The isolated nucleic acid of claim 54 , wherein the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:113 claim 54 , 117 claim 54 , 119 claim 54 , 122 claim 54 , 124 claim 54 , 126 claim 54 , 128 claim 54 , 130 claim 54 , and 132.56. The isolated nucleic acid of claim 54 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:111 and 115.57. The isolated nucleic acid of claim 54 , wherein the antibody comprises a heavy chain variable region and a light chain variable region claim 54 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:111 and 115 claim 54 , and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:113 claim 54 , 117 claim 54 , 119 claim 54 , 122 claim 54 , 124 claim 54 , 126 claim 54 , 128 claim 54 , 130 claim 54 , and 132.58. The ...

Influenza A H7N9 virus therapies

The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.

Anti-influenza B virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 1. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:191;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:197,thereby treating, inhibiting, or preventing influenza A virus infection in the individual.2. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises a heavy chain variable region and a light chain variable region , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:234 , and the light chain variable region comprises the amino acid sequence of SEQ ID NO:235 , thereby treating , inhibiting , or preventing influenza A virus infection in the individual.3. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount ...

INHIBITION OF QUORUM SENSING-MEDIATED PROCESSES IN BACTERIA

Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods of inhibiting quorum sensing-mediated activity in Gram-negative bacteria are provided wherein the activity is pathogenicity, bioluminescence, siderophore production, type III secretion, or metalloprotease production.

ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same. 1. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza B virus hemagglutinin comprising three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:63;(b) HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:67, 68, 69, 70, 71, 72, 73, and 74;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:77;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:56;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:58; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:60.2. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:91.3. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.4. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region and a heavy chain variable region claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:91 claim 1 , and the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.5. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID ...

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

SCREENING METHODS FOR IDENTIFYING ANTIBODIES THAT BIND CELL SURFACE EPITOPES

Provided are assays or methods for identifying antibodies that bind to microorganisms, e.g., pathogenic microorganisms, such as bacteria other infectious agents. In some embodiments, the provided methods for identifying an antibody that binds the target microorganism involves gel encapsulation of antibody-producing cells in gel microdroplets with a target microorganism. Also provided are antibodies produced by the method. Also provided are antibodies that bind a conserved region or epitope across variants or species of 1. A method for identifying an antibody that binds a target microorganism , comprising:(a) obtaining a plurality of candidate antibody-producing cells;(b) encapsulating the plurality of candidate antibody-producing cells in gel microdroplets with a target microorganism; and(c) determining whether the antibody-producing cell(s) within the gel microdroplet produce an antibody that binds the target microorganism, thereby identifying an antibody that specifically binds to the target microorganism.2. The method of claim 1 , wherein:step (b) further comprises encapsulating, in the microdroplets, an epitope-comprising fragment of the target microorganism or a variant thereof; andstep (c) comprises determining whether the antibody identified as binding the target microorganism also binds the epitope-comprising fragment thereof within the same gel microdroplet.3. A method for identifying an antibody that binds a target microorganism claim 1 , comprising:(a) obtaining a plurality of candidate antibody-producing cells;(b) encapsulating the plurality of candidate antibody-producing cells in gel microdroplets with a target microorganism and with an epitope-comprising fragment of the target microorganism or a variant thereof; and(c) determining whether the antibody-producing cell(s) within the gel microdroplet produce an antibody that binds the target microorganism and/or epitope-comprising fragment thereof present in the same gel microdroplet, thereby identifying ...

ENRICHMENT OF ANTIGEN-SPECIFIC PLASMABLASTS

The present invention relates to methods for enrichment of antigen-specific plasmablasts. The methods are useful for the identification of antibodies, including rare antibodies which recognize more than one antigen. 1. A method for obtaining a plasmablast population enriched for plasmablasts having specificity to an antigen , the method comprising obtaining peripheral blood mononuclear cells (PBMCs) from a donor , contacting the PBMCs with the antigen or a fragment or portion thereof to obtain a PBMC/antigen pre-mix , transferring the PBMCs into the spleen of an immunocompromised animal , and isolating the plasmablasts from the spleen of the immunocompromised animal , thereby obtaining a plasmablast population enriched for plasmablasts having specificity to an antigen.2. The method of claim 1 , wherein the method further comprises washing the PBMCs to remove excess or unbound antigen from the PBMC/antigen pre-mix prior to transferring the PBMCs into the spleen of the immunocompromised animal.3. The method of claim 1 , wherein the donor is a donor previously exposed to the antigen or to a fragment of portion thereof.4. The method of claim 1 , wherein the method further comprises single-cell sorting of the plasmablasts.5. The method of claim 1 , wherein the method further comprises antigen-specific single-cell sorting of the plasmablasts.6. The method of claim 1 , wherein the method further comprises immunoglobulin cloning from the plasmablasts.7. A method for enriching antigen-specific plasmablasts claim 1 , the method comprising obtaining peripheral blood mononuclear cells (PBMCs) from a donor claim 1 , contacting the PBMCs with at least one antigen to obtain an PBMC/antigen pre-mix claim 1 , transferring the PBMCs into the spleen of an immunocompromised animal claim 1 , and isolating the plasmablasts from the spleen of the immunocompromised animal claim 1 , thereby enriching antigen-specific plasmablasts.8. The method of claim 7 , wherein the method further ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 1. An isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:191 and 192;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and(f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:197, 198, and 199.2. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 136 claim 1 , 140 claim 1 , 144 claim 1 , 146 claim 1 , 150 claim 1 , 152 claim 1 , and 235.3. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 134 claim 1 , 138 claim 1 , 142 claim 1 , 148 claim 1 , and 234.4. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:134 claim 1 , 138 claim 1 , 142 claim 1 , 148 claim 1 , and 234 claim 1 , and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:136 claim 1 , 140 claim 1 , 144 claim 1 , 146 claim 1 , 150 claim 1 , 152 claim 1 , and 235.5. The isolated anti-hemagglutinin antibody of ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 153-. (canceled)54. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:181;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:183;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:189,thereby treating, inhibiting, or preventing influenza A virus infection.55. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises a heavy chain variable region and a light chain variable region , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:115 , and the light chain variable region comprises the amino acid sequence of SEQ ID NO:117 , thereby treating , inhibiting , or preventing influenza A virus infection.56. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition ...

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

Screening methods for identifying antibodies that bind cell surface epitopes

Provided are assays or methods for identifying antibodies that bind to microorganisms, e.g., pathogenic microorganisms, such as bacteria other infectious agents. In some embodiments, the provided methods for identifying an antibody that binds the target microorganism involves gel encapsulation of antibody-producing cells in gel microdroplets with a target microorganism. Also provided are antibodies produced by the method. Also provided are antibodies that bind a conserved region or epitope across variants or species of Acenitobacter .

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

Microbial consortia for the treatment of disease

The present invention provides microbial consortia capable of stable engraftment in the gastrointestinal tract of a subject, and degradation of a disease-associated metabolic substrate, and methods of using the same.

Enrichment of antigen-specific plasmablasts

The present invention relates to methods for enrichment of antigen-specific plasmablasts. The methods are useful for the identification of antibodies, including rare antibodies which recognize more than one antigen.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

isolated anti-hemagglutinin antibodies, method of treating, inhibiting or preventing infections, composition, pharmaceutical composition, isolated nucleic acid, host cell, antibody production method and use of anti-hemagglutinin antibody

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

H7n9 influenza a therapies with anti-h7 virus antibodies

The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.

ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE

La presente invención proporciona anticuerpos de antihemaglutinina, composiciones que comprenden anticuerpos de antihemaglutinina y sus métodos de uso.

H7n9 influenza a therapies with anti-h7 virus antibodies

The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.

Anti-influenza b virus hemagglutinin antibodies and methods of use.

La presente invención proporciona anticuerpos de hemaglutinina contra el virus de la influenza B, composiciones que comprenden anticuerpos de hemaglutinina contra el virus de la influenza B y sus métodos de uso.

Anti-influenza b virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.

Consorcios microbianos para el tratamiento de enfermedad.

La presente invención proporciona consorcios microbianos capaces de injertarse de manera estable en el tracto gastrointestinal de un sujeto, y la degradación de un sustrato metabólico asociado con enfermedad, y métodos para usar los mismos.

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

Small molecule antagonists of bacterial quorum-sensing receptors

A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum . The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.

Anticuerpos de antihemaglutinina y metodos de uso.

La presente invención proporciona anticuerpos de antihemaglutinina, composiciones que comprenden anticuerpos de antihemaglutinina y sus métodos de uso.

Microbial consortia

The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.

Microbial consortia

The present disclosure provides microbial consortia comprising O. formigenes capable of stable engraftment in the gastrointestinal tract of a subject and methods of using and making the same.

Consorcio microbiano

La presente divulgación proporciona consorcios microbianos que comprenden O. formigenes capaces de injerto estable en el tracto gastrointestinal de un sujeto, y métodos de uso y preparación de los mismos.

Microbial consortia

The present disclosure provides microbial consortia comprising

Microbial consortia for the treatment of disease

Microbial consortia

High-complexity synthetic gut bacterial communities